Cardiac allograft vasculopathy (CAV) remains the Achilles' heel of long-term survival after
heart transplantation. Almost one-third of patients develop CAV by 5 years post-transplant …

Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …

As the rapidly aging population and the rising incidence of end-stage heart failure, extensive
research has been conducted on heart transplantation (HTx). Bibliometrics harbors the …

Background: Small studies have reported superiority of sirolimus (SRL) over calcineurin
inhibitor (CNI) in mitigating cardiac allograft vasculopathy (CAV) after heart transplantation …

Aims Cardiac allograft vasculopathy (CAV) is a major limitation to long-term survival
following cardiac transplantation. Conventional imaging modalities such as angiography …

When transplanted simultaneously, the liver allograft has been thought to have an
immunoprotective role on other organs; however, detailed analyses in simultaneous heart …

Cardiac allograft vasculopathy (CAV) is a unique accelerated form of coronary vascular
disease affecting heart transplant recipients. This complication is a significant contributor to …

The mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus are
increasingly used in cardiothoracic transplantation. Several recent clinical trials have …

BACKGROUND: Optical coherence tomography (OCT) is a novel intravascular imaging
modality with excellent spatial resolution. This study explored the utility of OCT in cardiac …

The demographics of patients undergoing heart transplantation in the United States have
shifted over the last 10 years, with an increasing number of racial and ethnic minorities …